Date:5/6/2009

h (AACR) Annual Meeting in Denver, Colorado. Results from nonclinical translational research studies identified potent voreloxin activity in breast cancer biopsies from both ductal and metastatic tumors. Activity compared favorably with compounds currently in clinical use for the treatment of breast cancer, including cisplatin and topoisomerase II inhibitors doxorubicin and etoposide. Data also established an enhanced sensitivity to voreloxin in BRCA2 mutant cell lines, indicating that BRCA mutant tumors may be particularly sensitive to voreloxin. These data complement previous reports of potent voreloxin activity in biopsies from triple-negative breast cancers (AACR 2008) and support a rationale for potential future investigation of voreloxin's clinical activity in breast cancer patients.

In March, all three of the Company's voreloxin abstracts submitted for consideration at the 45th American Society of Clinical Oncology (ASCO) Annual Meeting to be held in Orlando, Florida were accepted. Each abstract represents one of the ongoing clinical trials of voreloxin: single-agent voreloxin in newly diagnosed elderly acute myeloid leukemia (AML), voreloxin in combination with cytarabine in relapsed/refractory AML and single-agent voreloxin in women with platinum-resistant ovarian cancer. In lieu of a conference call today, Sunesis management will host a conference call during the ASCO Annual Meeting to discuss the voreloxin clinical data to be presented at that meeting. Below are the details of the voreloxin presentations and the conference call information will be provided via press release several days prior to the ASCO Annual Meeting, which begins May 29.

Saturday May 30, 8:00AM to 12:00PM (poster presentation)

Abstract #7048

Title: "A phase II study of voreloxin as single agent therapy for elderly patients (pts) with newly diagnosed acute myeloid leukemia (AML)."

Loca
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9
Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
5. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
8. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
9. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
10. Haemacure Reports Third Quarter 2007 Results
11. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion